Bright Minds Biosciences (Bright Minds Biosciences) Total Liabilities : $0.63 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Total Liabilities?

Bright Minds Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 was $0.63 Mil.

Bright Minds Biosciences's quarterly Total Liabilities increased from Sep. 2023 ($0.21 Mil) to Dec. 2023 ($0.64 Mil) but then declined from Dec. 2023 ($0.64 Mil) to Mar. 2024 ($0.63 Mil).

Bright Minds Biosciences's annual Total Liabilities increased from Sep. 2021 ($0.50 Mil) to Sep. 2022 ($1.16 Mil) but then declined from Sep. 2022 ($1.16 Mil) to Sep. 2023 ($0.21 Mil).

Bright Minds Biosciences Total Liabilities Historical Data

The historical data trend for Bright Minds Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Total Liabilities Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Total Liabilities

0.11

0.50

1.16

0.21

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial													0.76	0.55	0.21	0.64	0.63

Bright Minds Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bright Minds Biosciences's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.208	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.21

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	5.084	-	4.876
	=	0.21

Bright Minds Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.625	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.63

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	4.825	-	4.2
	=	0.63

Bright Minds Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.